EU Industry Sets Out Priorities In Structured Dialog
Digitalization, Greater EU Alignment And Boosting Manufacturing Urged
As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.
You may also be interested in...
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
While the European off-patent industry has welcomed the latest update to the EU’s industrial strategy, including a detailed analysis of European dependencies on the global API manufacturing network, it has urged the European Commission to go further and provide “tailored actions” to bolster local manufacturing.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.